[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Submit :: Contact ::
:: Volume 8, Number 1 (1-2017) ::
Back to browse issues page Caspian J Intern Med 2017, 8(1): 35-43
Effect of SeptimebTM as a new natural extract on severe sepsis: A randomized clinical trial
Alieh Pourdast, Maryam Sanaie, Sirous Jafari, Mostafa Mohammadi, Hossein Khalili, Gita Shafiee, Zeinab Ahadi, Mahsa Rostami, Saba Alizad, Ramin Heshmat *, Minoo Mohraz
Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran , ahadi.ze@gmail.com
Abstract:   (987 Views)

Background: Septimeb as a herbal medicine has regulatory effects on inflammation. This study set to evaluate the effects of Septimeb among patients with sepsis on inflammatory biomarkers and survival rate.

Methods: In this randomized clinical trial, 51 patients with sepsis from the ICU and medical ward of Imam Khomeini Hospital were divided into two groups: Septimeb (n=25) and control group (n=26). In the control group, the patients received a standard treatment only for 7 days, while Septimeb group received Septimeb (6cc vial with 500cc serum glucose infusion 5% daily for one to two hours) plus standard treatment of sepsis for 7 days. Then, blood samples were analyzed. APACHE (Acute Physiologic and Chronic Health Evaluation), SOFA (Sequential Organ Failure Assessment), and GCS (Glasgow Coma Score) values were calculated daily.

Results: Treatment with Septimeb showed a significant decrease in SOFA value (1.54±0.83) compared to the control group (2.39±0.88) (P<0.001) and a significant increase in GCS value (14.46±0.88) compared to the control group (12.86±1.78) (P<0.001).  Improvements of these values can confirm the potential of Septimeb in the reduction of severity of sepsis (P<0.05). There were significant decreases in lactate and blood sugar and WBC levels. In addition, inflammatory factors such as ESR (Septimeb group: 52.07±34.80, control group: 51.75±42.10, P=0.98) and CRP (Septimeb group: 48.86±23.21, control group: 49.93±36.22, P=0.92) decreased, but did not show a significant reduction.

Conclusion: Septimeb has positive effects on reduction of the severity of sepsis which leads to reduction of patients’ mortality rates.

Keywords: Sepsis, Septimeb, Infection, Inflammatory
Full-Text [PDF 514 kb]   (249 Downloads)    
Type of Study: Original Article | Subject: Infectious Diseases
Received: 2016/05/8 | Accepted: 2016/09/5 | Published: 2016/11/15
Send email to the article author

Add your comments about this article
Your username or email:

Write the security code in the box >



XML     Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Pourdast A, Sanaie M, Jafari S, Mohammadi M, Khalili H, Shafiee G, et al . Effect of SeptimebTM as a new natural extract on severe sepsis: A randomized clinical trial. Caspian J Intern Med. 2017; 8 (1) :35-43
URL: http://caspjim.com/article-1-755-en.html
Back to browse issues page Volume 8, Number 1 (1-2017)
Caspian Journal of Internal Medicine
Persian site map - English site map - Created in 0.048 seconds with 812 queries by yektaweb 3388